(VIANEWS) - Enova International (ENVA), Middlesex Water Company (MSEX), ResMed (RMD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Enova International (ENVA)
21.1% sales growth and 15.89% return on equity
Enova International, Inc., a technology and analytics company, provides online financial services in the United States, Brazil, Australia, and Canada. The company offers installment loans; line of credit accounts; receivables purchase agreements; CSO programs, including arranging loans with independent third-party lenders and assisting in the preparation of loan applications and loan documents; and bank programs, such as marketing services and loan servicing for near-prime unsecured consumer installment loan. It markets its financing products under the CashNetUSA, NetCredit, OnDeck, Headway Capital, The Business Backer, Simplic, and Pangea names. Enova International, Inc. was incorporated in 2011 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Enova International has a trailing twelve months EPS of $5.9.
PE Ratio
Enova International has a trailing twelve months price to earnings ratio of 9.59. Meaning, the purchaser of the share is investing $9.59 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.89%.Volume
Today's last reported volume for Enova International is 222137 which is 25.86% below its average volume of 299629.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Enova International's EBITDA is 58.31.
2. Middlesex Water Company (MSEX)
7.5% sales growth and 8.01% return on equity
Middlesex Water Company owns and operates regulated water utility and wastewater systems. It operates in two segments, Regulated and Non-Regulated. The Regulated segment collects, treats, and distributes water on a retail and wholesale basis to residential, commercial, industrial, and fire protection customers in parts of New Jersey, Delaware, and Pennsylvania. This segment also includes regulated wastewater systems in New Jersey and Delaware. The Non-Regulated segment provides non-regulated contract services for the operation and maintenance of municipal and private water and wastewater systems in New Jersey and Delaware. The company was incorporated in 1896 and is headquartered in Iselin, New Jersey.
Earnings Per Share
As for profitability, Middlesex Water Company has a trailing twelve months EPS of $1.84.
PE Ratio
Middlesex Water Company has a trailing twelve months price to earnings ratio of 33.45. Meaning, the purchaser of the share is investing $33.45 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.01%.3. ResMed (RMD)
6.2% sales growth and 21.66% return on equity
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, ResMed has a trailing twelve months EPS of $6.04.
PE Ratio
ResMed has a trailing twelve months price to earnings ratio of 31.49. Meaning, the purchaser of the share is investing $31.49 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.66%.4. The Joint Corp. (JYNT)
5.8% sales growth and 6.15% return on equity
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of January 27, 2021, the company operated approximately 550 locations in the United States. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Earnings Per Share
As for profitability, The Joint Corp. has a trailing twelve months EPS of $0.18.
PE Ratio
The Joint Corp. has a trailing twelve months price to earnings ratio of 50.28. Meaning, the purchaser of the share is investing $50.28 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.15%.